Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine for PLXNA1-amplified refractory advanced solid tumors
ChiCTR1900025481Phase 4Recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fludarabine in prostate cancer (PCa), pancreatic cancer (PC) and colon cancer, sponsored by Changhai Hospital. Primary endpoint: Maximum tolerated dose. Started Sep 2019; status: recruiting.
02
Drugs
fludarabine
03
Conditions
prostate cancer (PCa)pancreatic cancer (PC)colon cancer
Beyond the preview
Go deeper on ChiCTR1900025481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025481.